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BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteo-
sarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507
in patients with various subtypes of recurrent or refractory sarcomas. METHODS: Eligibility criteria included age 2 years and a diag-
nosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg=kg R1507 intra-
venously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was
performed every 6 weeks34 and every 12 weeks thereafter. RESULTS: From December 2007 through August 2009, 163 eligible
patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included
OS (n538), RMS (n536), SS (n523), and other sarcomas (n566). The overall objective response rate was 2.5% (95% confidence
interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient
with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a 50% decrease in tumor
size that lasted for <4 weeks. The median progression-free survival was 5.7 weeks, and the median overall survival was 11 months. The
most common grade 3=4 toxicities were metabolic (12%), hematologic (6%), gastrointestinal (4%), and general constitutional symp-
toms (8%). CONCLUSIONS: R1507 is safe and well tolerated but has limited activity in patients with recurrent or refractory bone and
soft tissue sarcomas. Additional studies to help identify the predictive factors associated with clinical benefit in selected histologies
such as RMS appear to be warranted. Cancer 2014;120:2448-56. VC 2014 American Cancer Society.
KEYWORDS: sarcoma, IGF-1R, SARC, insulin-like growth factor.
INTRODUCTION
The outcome for patients with advanced or recurrent bone and soft tissue sarcomas has remained unchanged over the past
20 years.1-3 Effective standard agents for this population are limited. Newer, more effective, and less toxic therapies are
urgently needed to improve the outcome of these patients.4-9 Genomic analysis of sarcomas has demonstrated that identi-
fication of targets and new therapeutics is particularly challenging.10
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The type I insulin-like growth factor receptor (IGF-
1R) is a tyrosine kinase receptor that belongs to the insulin
receptor family. Activation of the receptor by its ligands
IGF-1 and IGF-2 induces mitosis, protects cells against
apoptosis, and helps maintain a transformed phenotype.11
Blocking the IGF-1R decreases tumor proliferation by in-
hibiting v-akt murine thymoma viral oncogene homolog
(AKT)-mediated survival signals, and this response
appears to be correlated with elevated IGF-1R levels.12
In addition to Ewing sarcoma (ES),13,14 the IGF-1R
pathway has been implicated in the pathogenesis of other
bone and soft tissue sarcomas, including rhabdomyosar-
coma (RMS), osteosarcoma (OS), synovial sarcoma, des-
moplastic small round cell tumor, and solitary fibrous
tumor.14 In RMS tumors and cell lines, IGF-2 functions
as an autocrine and motility growth factor, and IGF-1R is
1 of the targets for the paired box 3-forkhead box O1A
(PAX3-FOXOA1) fusion transcript of alveolar RMS.15,16
Antibodies against IGF-1R are safe and exhibit clini-
cal activity in patients with recurrent ES and neuroendo-
crine tumors.17-21 R1507 (F. Hoffman-LaRoche, Basel,
Switzerland) is a fully human immunoglobulin G1
(IgG1)-type monoclonal antibody directed against the
human IGF-1R, and the Sarcoma Alliance for Research
through Collaboration (SARC) conducted a phase 2,
multiarm study with this agent in multiple sarcoma sub-
types. On the basis of preclinical data, the authors
believed that OS, RMS, desmoplastic small round cell tu-
mor, and ES were important subtypes for inclusion in
that trial. The outcomes of patients with ES have been
reported separately.18 The current report details the
results from a phase 2 study in patients with recurrent or
progressive RMS, high-grade OS, synovial sarcoma, and
other soft tissue sarcomas, including translocation-
associated sarcomas like alveolar soft part sarcoma, des-
moplastic small round cell tumor, extraskeletal myxoid
chondrosarcoma, clear cell sarcoma, and myxoid liposar-
coma, who received treatment with R1507.
MATERIALS AND METHODS
Eligibility included a centrally histologically verified diag-
nosis of RMS, high-grade OS, synovial sarcoma, or other
sarcoma; age>2 years; a life expectancy of at least 6 weeks;
a Karnofsky=Lansky performance status>70%; bidimen-
sionally measurable disease by computed tomography or
magnetic resonance imaging; adequate bone marrow,
liver, and renal function; and off chemotherapy for at least
3 weeks. Patients with central nervous system disease had
no overt neurologic deficit, were off glucocorticoids for at
least 4 weeks, and were off irradiation for >6 weeks.
Patients were excluded if they had significant unrelated
systemic illness, prior hypersensitivity reactions to mono-
clonal antibodies, treatment within 2 weeks of study entry
with pharmacologic doses of corticosteroids or other
immunosuppressive agents, prior therapy with insulin-
like growth factor inhibitors, poorly controlled diabetes,
or a history of solid organ transplantation or other malig-
nancy within 5 years.
Drug Administration
R1507 was administered intravenously at a dose of 9
mg=kg in 100 mL normal saline weekly (1 cycle) over 90
minutes during the initial infusion and, in the absence of
any reactions, over 60 minutes during subsequent infusions.
Pharmacokinetic samples
Pharmacokinetic (PK) levels were quantified in serum
using an enzyme-linked immunosorbent assay (ELISA)
(25 ng=mL was used as the lower limit of quantification).
Blood samples (5 mL) were obtained before the first infu-
sion; at the end of the infusion; and 24 hours, 72 to 96
hours, and 168 hours after the infusion in week 1. For
graphic representation of the peak (Cmax) and trough
(Cmin) values throughout the study, data were pooled
from patients with this intense PK schedule and from
patients whose PK samples were drawn with a less intense
schedule during weeks 1, 2, 4, 6, 9, and 12 just before dos-
ing and at the end of the infusion.
Pharmacodynamic methods
Serum levels of total IGF-1 were analyzed by ELISA
(DSL-10-5600 Active IGF-I ELISA Kit; Beckman
Coulter, Inc., Jersey City, NJ). Samples were collected
before the first dose and 24 hours after the infusion. Sam-
ples also were collected before the second, sixth, and 12th
intravenous doses.
Clinical and Laboratory Investigations
Investigations included a baseline physical examination,
complete blood count, chemistries, pregnancy test, elec-
trocardiogram, antihuman antibodies, imaging for tumor
measurements, and a positron emission tomography scan,
which was repeated at day 9 and at week 18 for responders
according to World Health Organization (WHO) crite-
ria.22 Subsequent physical examinations, complete blood
counts, and chemistries were performed weekly for 6
weeks and every 3 weeks thereafter. Tumor imaging was
performed every 6 weeks 4 times and every 12 weeks
thereafter. Tumor imaging was centrally reviewed.
Response to therapy was evaluated using WHO cri-
teria.22 Off-study criteria included progressive disease,
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illness that prevented further administration of therapy,
unacceptable adverse events, patient withdrawal from the
study, a lapse >2 weeks since R1507 administration or
missing2 consecutive doses, death, loss to follow-up, or
an unacceptable condition that, in the opinion of the in-
vestigator, would prevent the patient from receiving fur-
ther therapy.
Statistical Methods
The primary endpoint was the best objective response,
which was assessed separately within each of the differ-
ent strata: OS, RMS, synovial sarcoma, and other sarco-
mas (alveolar soft part sarcoma, clear cell sarcoma,
desmoplastic small round cell tumor, extraskeletal myx-
oid chondrosarcoma, and myxoid liposarcoma).
Progression-free survival at 18 weeks was a secondary
objective. On the basis of the design of Green and
Dahlberg,23 a maximum of 35 patients would be
needed for the OS, RMS, and synovial sarcoma sub-
types. The trial would stop if zero of 20 eligible patients
achieved a response after the first stage; the probability
of early termination was 12% if the true response rate
was 10%. The null hypothesis would be rejected after
the second stage if >7 of 35 patients responded. With a
sample size of 35, the power to detect a 30% response
rate was 87% with a 1-sided a of 2%. For “other
sarcomas,” an analysis that considered each subtype sep-
arately was undertaken. A minimum of 10 eligible
patients were accrued to each group, and the trial would
stop if there were no responders in that subtype; other-
wise, 10 more patients would be accrued to that sub-
type. The null hypothesis of a 5% response rate would
be rejected in favor of the alternative hypothesis of a
30% response rate if >3 of 20 patients responded.
With a sample size of 20 eligible patients per cohort,
the power to detect a 30% response rate was 94.5%
with a 1-sided a of 1.5%. The probability of early ter-
mination was 60% if the true response rate was 5%.
R1507 serum-concentration time data were ana-
lyzed using noncompartmental analyses (WinNonlin
release 5.2.1; Pharsight Corporation, Mountain View,
Calif). End-of-infusion samples were used to estimate the
peak concentration (Cmax), and trough values (Cmin) were
determined from predose samples. The following phar-
macokinetic parameters were evaluated: area under the
concentration curve to the last measured time point
(AUC at 0-168 hours), clearance, and volume of distribu-
tion. The dosing schedule relative to the half-life did not
allow for appropriate estimation of the elimination half-
life (t1=2).
RESULTS
From December 31, 2007 through August 2009, 163 eli-
gible patients from 33 institutions were enrolled and
treated (Fig. 1). The median age at the time of enrollment
was 31 years (range, 7-85 years). Overall, 30 patients
(18%) were aged<18 years; and RMS and OS histologies
accounted for the majority of these cases (Table 1).
Study Treatment
In total, 1813 doses were administered to 163 patients.
The median number of treatment cycles was 6 (range, 1-
108 cycles) per patient: 38 patients with OS received 2 to
108 cycles or more, 23 patients with synovial sarcoma
received 2 to 59 cycles, 36 patients with RMS received 2
to 25 cycles, and 66 patients with other sarcomas received
between 1 and 71 cycles. The median dose of R1507 per
patient in mg=kg was 9.1 (range, 8.3-9.9 mg=kg).
Tumor Response and Clinical Outcome
The overall objective response rate was 2.5% (95% confi-
dence interval [CI], 0.7%-6.2%). Partial responses were
observed in 4 patients, including 2 patients with OS, 1
patient with RMS (embryonal subtype), and 1 patient
with an alveolar soft part sarcoma (Figs. 2, 3; Table 2).
The median duration of response was 12 weeks (range,
12.3-24 weeks), and responses were observed at 6 weeks
in 2 patients and at 12 weeks in the remaining 2 patients.
Three patients with RMS (3 alveolar subtype) (Fig. 2) and
Figure 1. This is a Consolidated Standards of Reporting Trials
(CONSORT) diagram of patients registered on this study.
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1 patient with myxoid liposarcoma had initial dramatic
tumor shrinkage (50%) at week 6 but progressed by the
time of the next assessment; and 2 additional patients (1
with RMS and 1 with myxoid liposarcoma) had partial
responses at the week-18 disease assessments, but they
were not confirmed at later assessments. Stable disease was
observed in 26% of patients, including approximately
one-third of patients in the other sarcoma category (41%
of those with alveolar soft part sarcoma, 32% of those
with extraskeletal myxoid chondrosarcoma, 19% of those
with desmoplastic small round cell tumor, and 10% of
those with myxoid liposarcoma), with a median duration
of 6.5 weeks. For all eligible patients, median overall sur-
vival was 11.2 months (95% CI, 9.4-13.1 months), and
progression-free survival was 5.7 weeks (95% CI, 5.6-5.9
weeks). Only 17% of patients (95% CI, 11.2%-22.6%)
were progression-free at 12 weeks, and 7% (95% CI,
3.4%-11.4%) were progression-free at 24 weeks. The
progression-free survival rates for patients with different
histologies are depicted in Figure 4. There were 22
patients (10 with OS, 7 with other sarcomas, 4 with syno-
vial sarcoma, and 1 with RMS) who were alive more than
2 years after enrollment on the protocol. These patients
received a median of 10 doses of R1507 (range, 5-108
doses). One patient was still receiving therapy after 175
weeks of treatment. There was no correlation between
response to therapy at week 12 and progression-free
survival.
Figure 2. The best individual changes in total lesion size from baseline are illustrated for all sarcoma types. WHO indicates World
Health Organization classification; PR, partial response; SD, stable disease; PD, progressive disease.
Figure 3. The best individual changes from baseline are illustrated according to sarcoma type. OSTEO indicates osteosarcoma;
RHABDO, rhabdomyosarcoma.
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Pharmacokinetics
Figure 5A illustrates the mean concentration time profile
observed after the first 9-mg=kg weekly dose. R1507 con-
centrations decreased to reach a mean trough (Cmin) value
of 62 lg=mL within the first dosing interval. On the basis
of the first dose, mean6 standard deviation Cmax values
of 216.86 90.8 lg=mL, an AUC from 0 to 168 hours of
17,3296 9682 lg*hour=mL, a volume of distribution of
56.26 17.8 L=kg, and a clearance of 8.56 2.5 mL per
day per kg were consistent with previously described
R1507 PK studies.18,20 These PK parameters were deter-
mined using data from 40 patients, and the interpatient
variability (coefficient of variation percentage) ranged
from 30% to 42%. Both Cmax and Cmin values increased
over the course of 12 weeks, and there was some evidence
of a PK plateau after 6 weeks of treatment (Fig. 5B).These
results are consistent with estimates of a previously
reported long elimination half-life.20 The observations of
the respective Cmin and Cmax values were made by using
all patients who had data available, including N5 155
and 142 patients (week 1), respectively; 144 and 140
patients (week 2), respectively; 139 and 37 patients (week
4), respectively; 108 and 106 patients (week 6), respec-
tively; 13 and 12 patients (week 9), and 42 and 35 patients
(week 12), respectively. Percentage changes in total IGF-1
levels from baseline are illustrated in Figure 6.
Prognostic Factors
Multivariate Cox regression analysis identified that an
IGF-1 level >110 ng=mL, a Karnofsky performance sta-
tus >90%, older age at diagnosis, and a diagnosis of OS
were associated with longer survival (Table 3, Fig. 4).
Among 92 patients who had samples available for analysis
at week 6 of therapy, there were no significant associations
between levels or changes in total IGF-1 and clinical
outcome.
Toxicities
In total, 91 patients experienced adverse events related to
R1507, including 37 grade 1 events, 37 grade 2 events, 15
grade e events, and 2 grade 4 events. The most common
R1507-related adverse events included fatigue (n5 33),
nausea (n5 23), hyperglycemia (n5 15), and muscle
spasms (n5 14). The most common grade 3 and 4 toxic-
ities related to treatment were hyperglycemia (n5 4),
dehydration (n5 3), and fatigue (n5 3) (Table 4).
DISCUSSION
To our knowledge, this is the largest reported prospective,
multi-institutional study in bone and soft tissue sarcomas
TABLE 2. Best Response by Histologic Subtype Among 163 Eligible Patients
No. of Patients (%)
Best Response OS, n 5 38 SS, n 5 23 RMS, n 5 36 Other, n 5 66 Total, n 5 163a
Partial response 2 0 1 1 4 (2)
Stable disease 10 4 6 22 42 (26)
Progressive disease 26 17 26 40 109 (67)
Not evaluable/inadequate assessment 0 2 3 3 8 (5)
Abbreviations: OS, osteosarcoma; RMS, rhabdomyosarcoma; SS, synovial sarcoma.
a Note that percentages have been rounded up.
TABLE 1. Clinical Characteristics of 163 Eligible
Patients
Characteristic No. of Patients (%)
Age Median [range] 31 [7–85]
Sex
Male 99 (60.7)
Female 64 (38.3)
Race
White 110 (67)
Black 15 (9)
Asian 9 (6)
Other 5 (3)
Not provided 24 (15)
Performance status, %
70 16 (10)
80 39 (24)
90 74 (46)
100 32 (20)
Histologic subtype
Osteosarcoma 38 (23)
Synovial sarcoma 23 (14)
Rhabdomyosarcoma 36 (22)
Alveolar 12
Embryonal 3
Unknown 21
Other 22 (14)
ASPS 9 (5)
CCS 12 (7)
DSRCT 11 (7)
EMC/MLS 12 (7)
No. of prior treatments
2 116
3 40
Unknown 7
Abbreviations: ASPS, alveolar soft part sarcoma; CCS, clear cell sarcoma;
DSRCT, desmoplastic small found cell tumor; EMC, extraskeletal myxoid
chondrosarcoma; MLS, myxoid liposarcoma.
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investigating the activity of a monoclonal antibody against
the IGF-1R. Our study demonstrates that R1507 has lim-
ited activity in selected bone and soft tissue sarcomas and
has a very favorable toxicity profile. In our study, 2.5% of
patients experienced a measurable objective response as
defined by WHO criteria, and only 17% were
progression-free at 12 weeks, suggesting that the drug is
inactive in these patient groups.24 However, a careful
analysis of our data demonstrates that patients with RMS
and OS may benefit from this therapy, and further study
appears to be warranted in these subgroups (Fig. 2). The
results of other published sarcoma trials using various
monoclonal antibodies directed against IGF-1R are pro-
vided in Table 5.17,18,21,25-27
It is unclear why clinical responses were disappoint-
ingly low in our study. From our data, we were able to
identify distinct subsets of patients that responded differ-
ently to IGF-1R–blocking therapy. The first group, which
accounted for about 66% of patients, failed to exhibit a
clinical response and progressed after a median of 2 cycles
of R1507. It is possible that these patients have low levels
of IGF-1R receptors,13 as recently demonstrated in ES
cell lines by flow cytometry,28 and=or intrinsic expression
or activation of macrophage-stimulating 1 receptor
(MST1R). MST1R is a met proto-oncogene (MET)-
related protein tyrosine kinase expressed in 48% of
embryonal RMS and 71% of alveolar RMS. It modulates
IGF-1R activity through the activation of ribosomal pro-
tein S6 (RPS6) and may be a mechanism of innate resist-
ance to anti-IGF-1R therapy.29 Additional resistance
mechanisms may include constitutively up-regulated
phosphorylated AKT (p-AKT) and=or mammalian target
of rapamycin (mTOR) secondary to the up-regulation of
TORC2 (CREB-regulated transcription coactivator 2) or
a compensatory switch that favors IGF-II=IR-A depend-
ency.30,31 Laboratory studies to elucidate these potential
mechanisms are currently being performed on collected
tissue specimens. Approximately 25% of our patients in
the other sarcoma category had stable disease; however
this was short lived (about 6 weeks) and included patients
who had tumors that are known for their indolent clinical
course, such as alveolar soft part sarcoma. Thus, the clini-
cal benefit of this agent in this patient group could not be
accurately assessed. A small group of patients had dra-
matic and sustained responses to R1507. This group likely
had tumors that expressed high levels of IGF-1R recep-
tors, lacked insulin receptor expression, had low levels of
BCL-2, and also may have had decreased or absent expres-
sion of MST1R.21,32,33 A third group of patients had
Figure 4. Progression-free survival for all eligible patients.
Values in parentheses are the 95% confidence interval for me-
dian progression-free survival in weeks. OSTEO indicates os-
teosarcoma; RHABDO, rhabdomyosarcoma.
Figure 5. Changes in R1507 concentrations are illustrated. (A)
The mean concentration time profile observed after the first
weekly dose is shown. (B) Peak values (Cmax) (top horizontal
line) and trough values (Cmin) (bottom horizontal line)
increased over the course of 12 weeks with some evidence
for a pharmacokinetic plateau after 6 weeks of treatment.
Vertical lines indicate the standard deviations.
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transient responses followed by resistance, suggesting the
subsequent activation of alternative signaling pathways,
which may include platelet-derived growth factor receptor
(PDGFR), v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2 (ERBB2), epidermal growth factor
receptor (EGFR), or MET.34-36 The latter mechanism of
resistance is being recognized increasingly in a variety of
tumor systems.37 Finally, the low response rates observed
in our trial could have been related to inadequate drug
dosing, because R1507 tumor biodistribution reportedly
was correlated with tumor response in a panel of sarcoma
xenografts using immuno–single-photon emission com-
puted tomography imaging.38 The initial dose of 9 mg=kg
per week was based on phase 1 studies that demonstrated
a median half-life of 8 to 10 days in concentrations that
exceeded 20 lg=mL,20 a concentration expected to satu-
rate >90% of the IGF-1 receptors. Our current data are
consistent with previous observations.18 However,
ongoing PK studies suggest that high serum peak levels
are more important and that dosing 27 mg=kg every 3
weeks appears to be more efficacious than the same dose
divided weekly.18
The median overall survival in our patients was 13
months. This is similar to the survival reported in other
studies for patients with advanced RMS, OS, and synovial
sarcomas, emphasizing the critical need for effective thera-
pies in the relapsed setting. Although R1507 is much less
toxic than more the traditional cytotoxic chemotherapies
used for these malignancies in the refractory setting, the
response rates are lower.
Although the company has halted development of
this drug, we believe that IGF-1R inhibitors may play a
role in the treatment of selected sarcomas, particularly ES
and RMS. However, it will be crucial to incorporate the
development of both positive and negative prospective
biomarkers into future clinical studies. For example, some
tumors have undetectable levels of the IGF-1R on their
surface, which would lead to a prediction that such
patients would be unlikely to respond to IGF-1R block-
ade. Thus, the incorporation of a sensitive, quantitative
assay for the expression of the IGF-1R as a selection crite-
ria would likely lead to an increase in response rates.
Unfortunately, the presence of the IGF-1R does not
Figure 6. The total percentage change in insulin-like growth
factor-1 (IGF-1) from baseline (BL) is illustrated in weeks.
TABLE 3. Multivariate Results for Overall Survival
Multivariate Analysis
Variable No./Total No. (%) HR [95% CI] P
Total IGF-1 110 ng/mL
at baseline
118/135 (87) 0.35 [0.20–0.62] <.001
Age at randomization 135 (100) 0.99 [0.97–1.00] .020
Osteosarcoma 32/135 (24) 0.57 [0.35–0.93] .025
KPS 90 88/135 (65) 0.64 [0.42–0.97] .035
Abbreviations: CI, confidence interval; HR, hazard ratio; IGF-1, insulin-like
growth factor 1; KPS, Karnofsky performance status.
aP values were determined using the Wald chi-square test in Cox
regression.
TABLE 4. Grade 3 and 4 Toxicity Events
No. of Events
Adverse Event Grade 3 Grade 4
Total
Grade 3
Hematologic
Hemoglobin 1 0 1
Lymphopenia 1 0 1
Thrombocytopenia 0 1 1
Laboratory abnormalities
Blood alkaline phosphatase
increased
1 0 1
Blood bilirubin increased 1 0 1
Blood calcium decreased 1 0 1
Gamma-glutamyltransferase
increased
1 0 1
Hyperglyemia 4 0 4
Hyponatremia 2 0 2
Transaminases increased 1 0 1
Nonhematologic
Adrenal hemorrhage 1 0 1
Asthenia 1 0 1
Back pain 1 0 1
Decreased appetite 1 0 1
Deep vein thrombosis 1 0 1
Dehydration 3 0 3
Fatigue 3 0 3
Intestinal perforation 0 1 1
Musculoskeletal pain 1 0 1
Nausea 1 0 1
Maximum grade of any
adverse event
15 2 17
Original Article
2454 Cancer August 15, 2014
positively predict a response to anti-IGF-1R therapy, and
predictive biomarkers of response clearly are needed. This
probably will require prospective biopsies before entry on
study so that tumors can be studied for activation of sig-
naling pathways that hopefully could identify predictors
of response. Furthermore, such analysis also may help to
identify the potential activation of resistance pathways,
leading to rational combination therapies that could
include mTOR inhibitors, vascular endothelial growth
factor inhibitors, EGFR inhibitors, and=or Src family ki-
nase inhibitors.39-43
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improved overall survival
Figitumumab (Juergens 201121) Ewing, n 5 123; osteosarcoma,
n 5 11; other, n 5 4
138 Ewing, n 5 16 High pretreatment free
IGF-1 levels and total circulating
IGF-1 were correlated
with improved survival
Ganitumab (Tap 201225) Ewing, n 5 22; DSRCT, n 5 16 38 Ewing, n 5 1;
DSRCT, n 5 1
No relation between
baseline IGF-1 and response
Dalotuzumab (Atzori 201126) Ewing, n 5 6; bone, n 5 3 80 0 Mean serum IGF-1 and IGF-BP3
levels increased after 5 wks of therapy,
and treatment with dalotuizumab
decreased the mean H-scores of
IGF-1R in tumor and skin as well as
pS6, pEIF4G, pMAK, EGFR, and Ki-67
Cixutumab (Schoffski 201327) RMS, n 5 17; LMS, n 5 22;
adipocytic sarcoma, n 5 37;
synovial sarcoma, n 5 17;
Ewing, n 5 17
111 Ewing, n 5 1;
adipocytic sarcoma,
n 5 1
Abbreviations: DSRCT, desmoplastic small round cell tumor; EGFR, epidermal growth factor receptor; IGFBP3, insulin-like growth factor-binding protein 3;
LMS, leiomyosarcoma; pEIF4G, phosphorylated eukaryotic translation initiation factor 4 gamma; pS6, phosphorylated ribosomal protein S6; RMS,
rhabdomyosarcoma.
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